4D Molecular Therapeutics (FDMT) Operating Expenses (2020 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at 4D Molecular Therapeutics was $289.12 million, up 31.2% year-over-year; for FY2025, it came in at $244.76 million, up 30.3% from FY2024.

• Annual Operating Expenses has increased for six consecutive years, with a five-year compound annual growth rate of 28.3% (FY2020 to FY2025).
• In prior years, 4D Molecular Therapeutics' Operating Expenses was $187.88 million in FY2024 (+40.6%), $133.59 million in FY2023 (+18.1%), $113.16 million in FY2022 (+26.6%) and $89.37 million in FY2021 (+27.2%).
• The Q2 2026 figure stands as the highest quarterly Operating Expenses in data going back to Q1 2020.
• On a year-over-year basis, Operating Expenses has increased in each of the last 22 quarters, with growth averaging 38.4% over the last eight quarters.
• The year-over-year growth in Operating Expenses has ranged between 10.1% (Q1 2023) and 57.7% (Q3 2021) over the last five years.
• According to Business Quant data, Operating Expenses for the three prior quarters was $76.67 million (Q1 2026), $70.38 million (Q4 2025) and $61.28 million (Q3 2025).